Behavioral and psychological symptoms in dementia: Description and management;Pratique neurologique les symptômes psychologiques et comportementaux de la démence: Description et prise en charge

Revue Neurologique

Volumn 161, Issue 3, 2005, Pages 357-366

  Benoit, M ^a   Brocker, P ^b   Clement, J P ^c   Cnockaert, X ^d   Hinault, P ^e   Nourashemi, F ^f   Pancrazi, M P ^g   Portet, F ^h   Robert, P ^a   Thomas, P ^c   Verny, M ⁱ  

^a PASTEUR HOSPITAL   (France)

^b University of Côte d'Azur   (France)

^c Service de Psychiatrie   (France)

^d CH Chubert   (France)

^e Service de Neurologie   (France)

^f Toulouse University   (France)

^g Hôpital de Courbevoie   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LORAZEPAM; MEMANTINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAPRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZOLPIDEM; ZOPICLONE; NOOTROPIC AGENT;

ALZHEIMER DISEASE; BEHAVIOR; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONFUSION; CONSTIPATION; DEMENTIA; DIAGNOSTIC VALUE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL SOCIETY; MENTAL DISEASE; META ANALYSIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; URINE RETENTION; AGED; CONSENSUS DEVELOPMENT; FRANCE; NOMENCLATURE; PSYCHOLOGICAL ASPECT;

AGED; BEHAVIOR; DEMENTIA; FRANCE; HUMANS; NOOTROPIC AGENTS; PSYCHOTROPIC DRUGS; TERMINOLOGY;

EID: 20144388359     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(05)85064-7     Document Type: Conference Paper

References (123)

1. ALLAIN H, DAUTZENBERG PH, MAURER K, SCHUCK S, BONHOMME D, GERARD D. (2000a). Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl), 148: 361-366.
2. ALLAIN H, SHUCK S, BENTUE-FERRER D. (2000b). Anxiolytics in the treatment of behavioral ans psychological symptoms of dementia. International Psychogeriatrics, 12: 281-289.
3. ANAES. (2003). Prise en charge non médicamenteuse de la maladie d'Alzheimer et des troubles apparentés, Paris.
4. ATTIAS-DONFUT C. (1995). Les solidarités entre générations: vieillesse, famille, état. Essais et Recherches, Paris.
5. BAINS J, BIRKS JS, DENING TR. (2002). The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev: CD003944.
6. BARTHALOT C. (2001). Animation thérapeutique et thérapie facilitée par l'animal. Soins Gerontologiques, 30: 41-44.
7. BASS DM, NOELKER LS, RECHLIN LR. (1996). The moderating influence of service use on negative caregiving consequences. J Gerontol B Psychol Sci Soc Sci, 51: S121-131.
8. BENNET D, GILLEY DW, WILSON RS. (1992). Rate of cognitive decline and neuroleptic use in Alzheimer's disease. Neurology, 42: 276.
9. BENOIT M, KOULIBALY PM, MIGNECO O, DARCOURT J, PRINGUEY DJ, ROBERT PH. (2002). Brain perfusion in Alzheimer's disease with and without apathy: a SPECT study with statistical parametric mapping analysis. Psychiatry Res, 114: 103-111.
10. BENOIT M, STACCINI P, BROCKER P et al. (2003). [Behavioral and psychologic symptoms in Alzheimer's disease: results of the REAL.FR study]. Rev Med Interne, 24 (Suppl 3): 319s-324s.
11. BIEGEL DE, BASS DM, SCHULZ R, MORYCZ R. (1993). Predictors of in-home and out-of-home service use by family caregivers of Alzheimer's disease patients. J Aging Health, 5: 419-438.
12. BRODATY H, GREEN A, KOSCHERA A. (2003). Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc, 51: 657-664.
13. BURGIO LD, BUTLER FR, ROTH DL, HARDIN JM, HSU CC, UNG K. (2000). Agitation in nursing home residents: the role of gender and social context. Int Psychogeriatr, 12: 495-511.
14. BURKE WJ, DEWAN V, WENGEL SP, ROCCA-FORTE WH, NADOLNY GC, FOLKS DG. (1997). The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry, 12: 519-525.
15. CALIFORNIA WORKGROUP ON GUIDELINES FOR ALZHEIMER'S DISEASE MANAGEMENT. (2002). Guidelines for Alzheimer's disease management. California Workgroup on guidelines for Alzheimer's disease management, Los Angeles.
16. CHAN DC, KASPER JD, BLACK BS, RABINS PV. (2003). Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: the Memory and Medical Care Study. Int J Geriatr Psychiatry, 18: 174-182.
17. CHARAZAC P. (2001). Psychothérapies du sujet âgé. Encyclop Med Chir (Psychiatrie), 37.
18. CHESTON R. (1998). Psychotherapeutic work with people with dementia: a review of the literature. Br J Med Psychol, 71 (Pt 3): 211-231.
19. CLARK WS, STREET JS, FELDMAN PD, BREIER A. (2001). The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry, 62: 34-40.
20. COHEN-MANSFIELD J. (1989). Agitation in the elderly. In: N Bilig, et P Rabins (Eds.), Advances in psychosomatic medicine: Geriatric psychiatry. Karger, S., Switzerland, pp. 101-113.
21. CUMMINGS JL. (2000). Cholinesterase inhibitors: A new class of psychotropic compounds. Am J Psychiatry, 157: 4-15.
22. CUMMINGS JL, BACK C. (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry, 6: S64-78.
23. CUMMINGS JL, FAIRBANKS L, MASTERMAN DL. (1999). Strategies for analysing behavioural data in clinical trials involving patients with Alzheimer's disease. Int J Neuropsychopharmcol, 2: 59-66.
24. CUMMINGS JL, MEGA MS, GRAY K, ROSEMBERG-THOMPSON S, GORNBEIN T. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology, 44: 2308-2314.
25. DAVIES RK, TUCKER GJ, HARROW M, DETRE TP. (1971). Confusional episodes and antidepressant medication. Am J Psychiatry, 128: 95-99.
26. DE DEYN PP, RABHERU K, RASMUSSEN A et al. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53: 946-955.
27. DEVANAND DP, JACOBS DM, TANG MX et al. (1997). The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry, 54: 257-263.
28. DEVANAND DP, PELTON GH, MARSTON K et al. (2003). Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry, 18: 123-130.
29. DONALDSON C, TARRIER N, BURNS A. (1998). Determinants of carer stress in Alzheimer's disease. Int J Geriatr Psychiatry, 13: 248-256.
30. DONE DJ, THOMAS JA. (2001). Training in communication skills for informal carers of people suffering from dementia: a cluster randomized clinical trial comparing a therapist led workshop and a booklet. Int J Geriatr Psychiatry, 16: 816-821.
31. DOODY RS, STEVENS JC, BECK C et al. (2001). Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56: 1154-1166.
32. EDELL WS, TUNIS SL. (2001). Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. Am J Geriatr Psychiatry, 9: 289-297.
33. FELDMAN H, GAUTHIER S, HECKER J, VELLAS B, SUBBIAH P, WHALEN E. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57: 613-620.
34. FINKEL SI, COSTA E, SILVA J, COHEN G, MILLER S, SARTORIUS N. (1996). Behavioral and Psychological Signs and Symptoms of Dementia: A consensus Statement on Current Knowledge and Implications for research and Treatment. International Psychogeriatrics, 8: 497-500.
35. GAGNON D. (1996). A review of reality orientation (RO), validation therapy (VT), and reminiscence therapy (RT) with Alzheimer's client. Physical Occup Ther Geriatr, 14: 61-77.
36. GERDNER LA, BUCKWALTER KC, REED D. (2002). Impact of a psychoeducational intervention on caregiver response to behavioral problems. Nurs Res, 51: 363-374.
37. GILHOOLY ML. (1984). The impact of caregiving on care-givers: factors associated with the psychological well-being of people supporting a dementing relative in the community. Br J Med Psychol, 57 (Pt 1): 35-44.
38. GILLIN JC, BYERLEY WF. (1990). Drug therapy: the diagnosis and management of insomnia. N Engl J Med, 322: 239-248.
39. GITLIN LN, CORCORAN M, WINTER L, BOYCE A, HAUCK WW. (2001). A randomized, controlled trial of a home environmental intervention: effect on efficacy and upset in caregivers and on daily function of persons with dementia. Gerontologist, 41: 4-14.
40. GONZALEZ-SALVADOR MT, ARANGO C, LYKETSOS CG, BARBA AC. (1999). The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry, 14: 701-710.
41. HEALTH COUNCIL OF THE NETHERLANDS. (2002). Dementia. HCN, The Hague.
42. HEPBURN KW, TORNATORE J, CENTER B, OSTWALD SW. (2001). Dementia family caregiver training: affecting beliefs about caregiving and caregiver outcomes. J Am Geriatr Soc, 49: 450-457.
43. HIRONO N, MEGA MS, DINOV ID, MISHKIN F, CUMMINGS JL. (2000). Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. Arch Neurol, 57: 861-866.
44. HOFF AL, SHUKLA S, HELMS P et al. (1990). The effects of nortriptyline on cognition in elderly depressed patients. J Clin Psychopharmacol, 10: 231-232.
45. HOLZER JC, GITELMAN DR, PRICE BH. (1995). Efficacy of buspirone in the treatment of dementia with aggression. Am J Psychiatry, 152: 812.
46. HOOKER K, BOWMAN SR, COEHLO DP et al. (2002). Behavioral change in persons with dementia: relationships with mental and physical health of caregivers. J Gerontol B Psychol Sci Soc Sci, 57: 453-460.
47. HOPE T, KEENE J, GEDLING K, FAIRBURN CG, JACOBY R. (1998). Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriatr Psychiatry, 13: 682-690.
48. IPA. (2003). Behavioral and Psychological Symptoms of Dementia. Educational Pack.
49. JESTE DV, OKAMOTO A, NAPOLITANO J, KANE JM, MARTINEZ RA. (2000). Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry, 157: 1150-1155.
50. JESTE DV, ROCKWELL E, HARRIS MJ, LOHR JB, LACRO J. (1999). Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry, 7: 70-76.
51. JONES G. (1997). A review of Feil's validation method for communicating with and caring for dementia sufferers. Current opinion in psychiatry, 10: 326-332.
52. KASL-GODLEY J, GATZ M. (2000). Psychosocial interventions for individuals with dementia: an integration of theory, therapy, and a clinical understanding of dementia. Clin Psychol Rev, 20: 755-782.
53. KATONA CL, HUNTER BN, BRAY J. (1998). A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry, 13: 100-108.
54. KATZ IR, JESTE DV, MINTZER JE, CLYDE C, NAPOLITANO J, BRECHER M. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry, 60: 107-115.
55. KAUFER DI, CUMMINGS JL, CHRISTINE D. (1996). Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol, 9: 1-6.
56. KOTRLA KJ, CHACKO RC, HARPER RG, JHINGRAN S, DOODY R. (1995). SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry, 152: 1470-1475.
57. KYDD P. (2001). Using music therapy to help a client with Alzheimer's disease adapt to long-term care. Am J Alzheimers Dis Other Demen, 16: 103-108.
58. LAWLOR BA. (1996). Environmental and social aspects of behavioral disturbances in dementia, Int Psychogeriatr, 8 (Suppl 3): 259-261.
59. LEBERT F, PASQUIER F, PETIT H. (1994). Trazodone in the treatment of behaviour in frontotemporal dementia. J Clin Psychiatry, 55: 536-538.
60. LEVY ML, CUMMINGS JL, FAIRBANKS LA, BRAVI D, CALVANI M, CARTA A. (1996a). Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry, 153: 1438-1443.
61. LEVY ML, MILLER BL, CUMMINGS JL, FAIRBANKS LA, CRAIG A. (1996b). Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol, 53: 687-690.
62. LINDAU M, ALMKVIST O, JOHANSSON SE, WAHLUND LO. (1998). Cognitive and behavioral differentiation of frontal lobe degeneration of the non-Alzheimer type and Alzheimer's disease. Dement Geriatr Cogn Disord, 9: 205-213.
63. LYKETSOS CG, LOPEZ O, JONES B, FITZPATRICK AL, BREITNER J, DEKOSKY S. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA, 288: 1475-1483.
64. LYKETSOS CG, SHEPPARD JM, STEELE CD et al. (2000a). Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry, 157: 1686-1689.
65. LYKETSOS CG, STEINBERG M, TSCHANZ JT, NORTON MC, STEFFENS DC, BREITNER JC. (2000b). Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry, 157: 708-714.
66. MC SHANE R, KEENE J, GEDLING K, FAIRBURN C, JACOBY R, HOPE T. (1997). Do reuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. British medical journal, 70: 266-314.
67. MCDANIEL JH, HUNT A, HACKES B, POPE JF. (2001). Impact of dining room environment on nutritional intake of Alzheimer's residents: a case study. Am J Alzheimers Dis Other Demen, 16: 297-302.
68. MCKEITH I, DEL SER T, SPANO P et al (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, 356: 2031-2036.
69. MCKEITH LG, GALASKO D, KOSAKA K. (1996). Consensus guidelines for the clinical and pathologic diagnosis of demencia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 47: 1113-1124.
70. MCMAHON S, KERMODE S. (1996). a clinical trial of the effect of aromatherapy on motivational behaviour in a dementia care setting using a single subject design. Aust J Holist Nurs, 51: 47-49.
71. MEGA MS, LEE L, DINOV ID, MISHKIN F, TOGA AW, CUMMINGS JL. (2000). Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry, 69: 167-171.
72. MEGA MS, MASTERMAN DM, O'CONNOR SM, BARCLAY TR, CUMMINGS JL. (1999). The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol, 56: 1388-1393.
73. MEINS W, FREY A, THIESEMANN R. (1998). Pre-morbid personality traits in Alzheimer's disease: do they predispose to noncognitive behavioral symptoms? Int Psychogeriatr, 10: 369-378.
74. MIAS L. (2003). Suggestions pour aider à vivre au quotidien la Maladie d'Alzheimer (MA) et la Démence Sénile de Type Alzheimer (DSTA). http://membres.lycos.fr/papidoc/04alzheimsugg.html
75. MIGNECO O, BENOIT M, KOULIBALY PM et al. (2001). Perfusion brain spect and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in alzheimer's disease and nondemented patients. Neuroimage, 13: 896-902.
76. MITTELMAN MS, FERRIS SH, SHULMAN E, STEINBERG G, LEVIN B. (1996). A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA, 276: 1725-1731.
77. MORANO CL, BRAVO M. (2002). A psychoeducational model for Hispanic Alzheimer's disease caregivers. Gerontologist, 42: 122-126.
78. MORETTI R, TORRE P, ANTONELLO RM, CAZZATO G, BAVA A. (2003). Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol, 49: 13-19.
79. NYTH AL, GOTTFRIES CG. (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Br J Psychiatry, 157: 894-901.
80. OLIN JT, SCHNEIDER LS, KATZ IR et al. (2002). Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry, 10: 125-128.
81. PALEACU D, MAZEH D, MIRECKI I, EVEN M, BARAK Y. (2002). Donepezil for the treatment of behavioral symptoms in patients with Alzheimer's disease. Clin Neuropharmacol, 25: 313-317.
82. PANCRAZI M. (2003). Conduite à tenir devant des troubles psychologiques et comportementaux de la maladie d'Alzheimer. Revue Francophone de Gériatrie et de Gérontologie, X: 73-81.
83. PATTERSON C, GAUTHIER S, BERGMAN H et al. (2001). The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci, 28 (Suppl 1): 3-16.
84. PETRACCA GM, CHEMERINSKI E, STARKSTEIN SE. (2001). A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr, 13: 233-240.
85. PIGGOTT MA, PERRY EK, MARSHALL EF et al. (1998). Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biol Psychiatry, 44: 765-774.
86. POLLOCK BG, MULSANT BH, SWEET R et al. (1997). An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry, 5: 70-78.
87. PORSTEINSSON AP, TARIOT PN, ERB R, GAILE S. (1997). An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry, 5: 344-351.
88. REISBERG B, AUER SR, MONTEIRO IM. (1996). Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr 8 (Suppl 3): 301-308; discussion 351-354.
89. REISBERG B, DOODY R, STOFFLER A, SCHMITT F, FERRIS S, MOBIUS HJ. (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med, 348: 1333-1341.
90. ROBERT P. (2002). Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr Med Res Opin, 18: 156-171.
91. ROBERT PH, ALLAIN H. (2001). Clinical management of agitation in the elderly with tiapride. Eur Psychiatry, 16 (Suppl 1): 42-47.
92. ROBERT PH, BENOIT M. (2001). Bases neuroanatomiques des comportements et émotions. Encycl Med Chir Psychiatrie, Elsevier SAS, Paris 37-530-A-15: 1 p.
93. ROBERT PH, MÉDECIN I, VINCENT S, STACCINI P, CATTELIN F, GONI S. (1998). L'inventaire Neuropsychiatrique: validation de la version Française d'un instrument destiné à évaluer les troubles du comportement chez les sujets déments. L'année Gérontologique, 5: 63-87.
94. ROSLER M. (2002). The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl, 127: 20-36.
95. ROTH M, MOUNTJOY CQ, AMREIN R. (1996). Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry, 168: 149-157.
96. SAINSBURY R, COLINS C, DUFF G, HARRISON J, HAYDON R, WILKINSON T. (2002). New Zealand Guidelines Group. - Guidelines for the support and management of people with dementia.
97. SATLIN A, VOLICER L, ROSS V, HERZ L, CAMPBELL S. (1992). Bright light treatment of behavioral and sleep disturbances in patients with Alzheimer's disease. Am J Psychiatry, 149: 1028-1032.
98. SCHATZBERG AF, KREMER C, RODRIGUES HE, MURPHY GM, JR. (2002). Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry, 10: 541-550.
99. SCHNEIDER LS. (1996). Meta-Analysis of controlled pharmacologic trials. International Psychogeriatrics, 8: 375-379.
100. SCHNEIDER LS, POLLOCK VE, LYNESS SA. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatric Society, 38: 553-563.
101. SCHULZ R, BEACH SR. (1999). Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA, 282: 2215-2219.
102. SMALL GW, RABINS PV, BARRY PP et al. (1997). Diagnosis and treatment of Alzheimer disease and related disorders (consensus treatment). JAMA, 278: 1363-1371.
103. SMALL JA, GUTMAN G. (2002). Recommended and reported use of communication strategies in Alzheimer caregiving. Alzheimer Dis Assoc Disord, 16: 270-278.
104. SOBOW TM, MACZKIEWICZ M, KLOSZEWSKA I. (2001). Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease. Int J Geriatr Psychiatry, 16: 1108-1109.
105. SPECTOR A, ORRELL M, DAVIES S, WOODS R. (2002). Reminiscence therapy for dementia (Cochrane Review). The Cochrane Library, Issue 4, Oxford.
106. STREET JS, CLARK WS, GAMMON KS et al. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry, 57: 968-976.
107. SULTZER DL, GRAY KF, GUNAY I, BERISFORD MA, MAHLER ME. (1997). A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry, 5: 60-69.
108. TARIOT PN, ERB R, PODGORSKI CA et al. (1998). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry, 155: 54-61.
109. TARIOT PN, LOY R, RYAN JM, PORSTEINSSON A, ISMAIL S. (2002). Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev, 54: 1567-1577.
110. TARIOT PN, MACK JL, PATTERSON MB et al. (1995). The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry, 152: 1349-1357.
111. TARIOT PN, SCHNEIDER J, MINTZER JE. (2001). Safety and tolerability of divalproex sodium for the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double blind, placebo controlled trial. Curr Ther Res, 62.
112. TARIOT PN, SOLOMON PR, MORRIS JC, KERSHAW P, LILIENFELD S, DING C. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 54: 2269-2276.
113. THOMAS P, CHANTOIN-MERLET S, HAZIF-THOMAS C et al. (2002). Complaints of informal caregivers providing home care for dementia patients: the Pixel study. Int J Geriatr Psychiatry, 17: 1034-1047.
114. VOLKOW ND, LOGAN J, FOWLER JS et al. (2000). Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry, 157: 75-80.
115. WEINER MF, MARTIN-COOK K, FOSTER BM, SAINE K, FONTAINE CS, SVETLIK DA. (2000). Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. J Clin Psychiatry, 61: 487-492.
116. WHITLATCH CJ, ZARIT SH, VON EYE A. (1991). Efficacy of interventions with caregivers: a reanalysis. Gerontologist, 31: 9-14.
117. WILKINSON DG, HOCK C, FARLOW M, VAN BAELEN B, SCHWALEN S. (2002). Galantamine provides broad benefits in patients with "advanced moderate" Alzheimer's disease (MMSE < or = 12) for up to six months. Int J Clin Pract, 56: 509-514.
118. WOOLTORTON E. (2002). Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ, 167: 1269-1270.
119. WOOLTORTON E. (2004). Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ, 170: 1395.
120. WRAGG RE, JESTE DV. (1989). Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry, 146: 577-587.
121. ZARIT S, ORR N, ZARIT J. (1985). The hidden victims of Alzheimer's disease: families under stress. New York University Press, New York.
122. ZARIT S, STEPHENS M, TOWNSEND A. (1996). Stress reduction for family caregivers. Effects of daycare use, American Psychological Association, Toronto, Canada.
123. ZARIT S, ZARIT J. (1983). The memory and behavior problems checklist and the burden interview. Copyrighted and published by the author. Department of Individual and Family Studies, the Pensylvania State University, University Park, PA 16802, USA.